

Expert Perspectives on SGLT2 INHIBITORS:

Reviewing Their Role in Type 2 Diabetes, Heart Failure, and Chronic Kidney Disease

SUNDAY, SEPTEMBER 12, 2021

6:45 AM – 7:45 AM MT

Gaylord Rockies Hotel and Convention Center

ROOM: Colorado A

3700 North Gaylord Rockies Boulevard

Aurora, CO 80019

FEATURES

- Simulation animations
- Interactive, case-based learning
- Complimentary personalized online poster portal

FACULTY

Richard E. Pratley, MD
Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine

LEARNING OBJECTIVES

- Identify patients with T2DM, heart failure or chronic kidney disease who would benefit from an SGLT2 inhibitor
- Apply guidelines and scientific evidence to the management of cardiovascular and/or renal risk in patients with T2DM
- Explain the mechanisms of action of SGLT-2 inhibitors in T2DM, heart failure, and chronic kidney disease
- Analyze clinical trial data on the use of SGLT2 inhibitors for managing cardiovascular and/or renal risk in patients with T2DM

AGENDA

I.

SGLT2 Inhibitors

- A. Mechanism of action
 - Anti-hyperglycemic MOA
 - Extra-glycemic MOA
- B. Glycemic outcomes trials
- C. Results from CVOT
- D. Renal trials
- E. Heart failure trials
- F. Distinctions between agents in the class
- I. Indications
- G. Use in patients with/without diabetes
- H. Side effects/contraindications
- i. Recommendations/algorithms from clinical practice guidelines (simulation challenge: selecting patients who would benefit from SGLT2 inhibitors)
 - ADA
 - ACC
 - Others
- J. Use in patients with COVID-19

II. Cross-specialty collaboration

III. Case studies

IV. Conclusion/Q&A

This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM). This activity is supported by an independent medical education grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

This satellite symposium is not part of the scientific program as planned by the Heart Failure Society of America ASM Program Committee.

Accredited Sponsor: Heart Failure Society of America 